AIMS: Compact tryptase-positive round cell infiltrates of the bone marrow (TROCI-BM) are very rare histopathological findings and may pose challenging problems with regard to the cell type involved (either mast cells or basophilic granulocytes) and the exact diagnosis. METHODS: A selected panel of immunohistochemical markers against mast cell and basophil related antigens, including CD25, CD34, CD117/Kit, and the 2D7 antigen (which is found only in basophilic granulocytes) on a total of 410 routinely processed bone marrow biopsy specimens (including 88 cases of systemic mastocytosis (SM), 20 cases of chronic myeloid leukaemia (CML), 92 cases of myeloid neoplasms other than CML, and 210 controls with normal/reactive bone marrows). RESULTS: In total, 17 cases with TROCI-BM could be identified: 11 SM (including two cases of well-differentiated SM and two mast cell leukaemias; MCL), 2 myelomastocytic leukaemia (MML), 2 CML with excess of basophils (secondary basophilic leukaemia (CMLba)), and 2 tryptase positive acute myeloid leukaemia (AML). Regarding the cell types involved, TROCI-BM cells were found to express CD117/Kit in all cases of SM and MCL. In MML and tryptase postitive AML, TROCI-BM cells were found to coexpress CD34 and Kit. The basophil specific antigen 2D7 was only detected in CD34/Kit negative TROCI-BM cells in two patients with CMLba. The activating point mutation D816V was detected in 8/11 patients with SM but not in any of the other haematological malignancies. CONCLUSIONS: In summary, a total of six rare myeloid neoplasms may present with a novel immunohistochemical phenomenon tentatively termed TROCI-BM.
AIMS: Compact tryptase-positive round cell infiltrates of the bone marrow (TROCI-BM) are very rare histopathological findings and may pose challenging problems with regard to the cell type involved (either mast cells or basophilic granulocytes) and the exact diagnosis. METHODS: A selected panel of immunohistochemical markers against mast cell and basophil related antigens, including CD25, CD34, CD117/Kit, and the 2D7 antigen (which is found only in basophilic granulocytes) on a total of 410 routinely processed bone marrow biopsy specimens (including 88 cases of systemic mastocytosis (SM), 20 cases of chronic myeloid leukaemia (CML), 92 cases of myeloid neoplasms other than CML, and 210 controls with normal/reactive bone marrows). RESULTS: In total, 17 cases with TROCI-BM could be identified: 11 SM (including two cases of well-differentiated SM and two mast cell leukaemias; MCL), 2 myelomastocytic leukaemia (MML), 2 CML with excess of basophils (secondary basophilic leukaemia (CMLba)), and 2 tryptase positive acute myeloid leukaemia (AML). Regarding the cell types involved, TROCI-BM cells were found to express CD117/Kit in all cases of SM and MCL. In MML and tryptase postitive AML, TROCI-BM cells were found to coexpress CD34 and Kit. The basophil specific antigen 2D7 was only detected in CD34/Kit negative TROCI-BM cells in two patients with CMLba. The activating point mutation D816V was detected in 8/11 patients with SM but not in any of the other haematological malignancies. CONCLUSIONS: In summary, a total of six rare myeloid neoplasms may present with a novel immunohistochemical phenomenon tentatively termed TROCI-BM.
Authors: John-Hendrik Jordan; Gerit-Holger Schernthaner; Robert Fritsche-Polanz; Wolfgang R Sperr; Manuela Födinger; Andreas Chott; Klaus Geissler; Klaus Lechner; Hans-Peter Horny; Peter Valent Journal: Leuk Lymphoma Date: 2002-03
Authors: P Valent; H P Horny; L Escribano; B J Longley; C Y Li; L B Schwartz; G Marone; R Nuñez; C Akin; K Sotlar; W R Sperr; K Wolff; R D Brunning; R M Parwaresch; K F Austen; K Lennert; D D Metcalfe; J W Vardiman; J M Bennett Journal: Leuk Res Date: 2001-07 Impact factor: 3.156
Authors: H P Horny; C Sillaber; D Menke; E Kaiserling; M Wehrmann; B Stehberger; A Chott; K Lechner; K Lennert; P Valent Journal: Am J Surg Pathol Date: 1998-09 Impact factor: 6.394
Authors: W R Sperr; J H Jordan; M Baghestanian; H P Kiener; P Samorapoompichit; H Semper; A Hauswirth; G H Schernthaner; A Chott; S Natter; D Kraft; R Valenta; L B Schwartz; K Geissler; K Lechner; P Valent Journal: Blood Date: 2001-10-01 Impact factor: 22.113
Authors: J H Jordan; S Walchshofer; W Jurecka; I Mosberger; W R Sperr; K Wolff; A Chott; H J Bühring; K Lechner; H P Horny; P Valent Journal: Hum Pathol Date: 2001-05 Impact factor: 3.466
Authors: P Samorapoompichit; H P Kiener; G H Schernthaner; J H Jordan; H Agis; F Wimazal; M Baghestanian; A Rezaie-Majd; W R Sperr; K Lechner; P Valent Journal: Blood Date: 2001-10-15 Impact factor: 22.113
Authors: P Valent; K Sotlar; W R Sperr; L Escribano; S Yavuz; A Reiter; T I George; H C Kluin-Nelemans; O Hermine; J H Butterfield; H Hägglund; C Ustun; J L Hornick; M Triggiani; D Radia; C Akin; K Hartmann; J Gotlib; L B Schwartz; S Verstovsek; A Orfao; D D Metcalfe; M Arock; H-P Horny Journal: Ann Oncol Date: 2014-03-27 Impact factor: 32.976
Authors: Peter Valent; Wolfgang R Sperr; Karl Sotlar; Andreas Reiter; Cem Akin; Jason Gotlib; Hans-Peter Horny; Michel Arock Journal: Expert Rev Hematol Date: 2014-08-28 Impact factor: 2.929
Authors: Feryal A Ibrahim; Mohammad A J Abdulla; Dina Soliman; Ahmad Al Sabbagh; Zafar Nawaz; Susanna Jane Akiki; Hawraa Shwaylia; Mohamed A Yassin Journal: Am J Case Rep Date: 2020-05-13